TWI827530B - 包括對西地尼布進行固定的間歇給藥之方法 - Google Patents

包括對西地尼布進行固定的間歇給藥之方法 Download PDF

Info

Publication number
TWI827530B
TWI827530B TW106104799A TW106104799A TWI827530B TW I827530 B TWI827530 B TW I827530B TW 106104799 A TW106104799 A TW 106104799A TW 106104799 A TW106104799 A TW 106104799A TW I827530 B TWI827530 B TW I827530B
Authority
TW
Taiwan
Prior art keywords
cediranib
cancer
days
composition
administered
Prior art date
Application number
TW106104799A
Other languages
English (en)
Chinese (zh)
Other versions
TW201906610A (zh
Inventor
賽門 貝利
珍 肯德魯
托尼 何
史帝芬 羅伯特 渥吉
佩西 艾薇
艾力斯 柯恩
珉廷 李
Original Assignee
瑞典商阿斯特捷利康公司
美國衛生與公眾服務部
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司, 美國衛生與公眾服務部 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW201906610A publication Critical patent/TW201906610A/zh
Application granted granted Critical
Publication of TWI827530B publication Critical patent/TWI827530B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106104799A 2016-02-15 2017-02-14 包括對西地尼布進行固定的間歇給藥之方法 TWI827530B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
US62/295,421 2016-02-15

Publications (2)

Publication Number Publication Date
TW201906610A TW201906610A (zh) 2019-02-16
TWI827530B true TWI827530B (zh) 2024-01-01

Family

ID=59625551

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106104799A TWI827530B (zh) 2016-02-15 2017-02-14 包括對西地尼布進行固定的間歇給藥之方法

Country Status (16)

Country Link
US (1) US20210322415A1 (enExample)
EP (2) EP3417294B8 (enExample)
JP (2) JP6865762B2 (enExample)
KR (1) KR102830910B1 (enExample)
CN (1) CN109073650A (enExample)
AU (1) AU2017221268B2 (enExample)
CA (1) CA3014674C (enExample)
DK (1) DK3417294T3 (enExample)
ES (2) ES3074047T3 (enExample)
HU (1) HUE058114T2 (enExample)
MA (1) MA44251A (enExample)
MX (2) MX2018009867A (enExample)
PL (1) PL3417294T3 (enExample)
RU (1) RU2740849C2 (enExample)
TW (1) TWI827530B (enExample)
WO (1) WO2017142871A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140377285A1 (en) * 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
EP1796672A1 (en) * 2004-09-27 2007-06-20 AstraZeneca AB Cancer combination therapy comprising azd2171 and imatinib
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
WO2009104019A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
AR075239A1 (es) * 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2871589C (en) * 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140377285A1 (en) * 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
網路文獻 MICHAEL MEDINGER Antitumor and Antiangiogenic Activity of Cediranib in a Preclinical Model of Renal Cell Carcinoma ANTICANCER RESEARCH 2009
網路文獻 MICHAEL MEDINGER Antitumor and Antiangiogenic Activity of Cediranib in a Preclinical Model of Renal Cell Carcinoma ANTICANCER RESEARCH 2009; *
網路文獻 Paul La Rosée Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib Ann Hematol 2013 Oct;92 *

Also Published As

Publication number Publication date
EP3417294B8 (en) 2022-05-04
JP7271594B2 (ja) 2023-05-11
EP3417294B1 (en) 2021-12-01
RU2018131377A3 (enExample) 2020-06-02
CN109073650A (zh) 2018-12-21
PL3417294T3 (pl) 2022-05-09
KR102830910B1 (ko) 2025-07-04
EP3417294A1 (en) 2018-12-26
HUE058114T2 (hu) 2022-07-28
JP2021105039A (ja) 2021-07-26
AU2017221268B2 (en) 2024-02-15
EP4071174B1 (en) 2026-05-27
EP3417294A4 (en) 2019-08-14
KR20180125456A (ko) 2018-11-23
US20210322415A1 (en) 2021-10-21
ES3074047T3 (en) 2026-07-16
MA44251A (fr) 2018-12-26
MX2023007826A (es) 2023-07-07
RU2018131377A (ru) 2020-03-17
CA3014674A1 (en) 2017-08-24
TW201906610A (zh) 2019-02-16
ES2906813T3 (es) 2022-04-20
JP6865762B2 (ja) 2021-04-28
WO2017142871A8 (en) 2018-06-14
EP4071174A1 (en) 2022-10-12
RU2740849C2 (ru) 2021-01-21
DK3417294T3 (da) 2022-02-21
WO2017142871A1 (en) 2017-08-24
MX2018009867A (es) 2019-05-27
CA3014674C (en) 2024-06-18
AU2017221268A1 (en) 2018-08-30
JP2019504860A (ja) 2019-02-21

Similar Documents

Publication Publication Date Title
JP7271594B2 (ja) セジラニブの一定間欠投与を含む方法
US20200086139A1 (en) Combination therapy for the treatment of glioblastoma
BRPI0808635A2 (pt) Nanopartícula compreendendo rapamicina e albumina como agente anti-câncer
CN110730663B (zh) 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途
CA2860941C (en) Combination therapy for the treatment of ovarian cancer
JP2006316060A (ja) インドリノン化合物を用いた組合せ及びその方法
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20210015787A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
AU2025201610A1 (en) Methods and compositions comprising a KRasG12c inhibitor and a VEGF inhibitor for treating solid tumors
EP4159238A1 (en) Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
AU2021397214B2 (en) Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors
HK40000757B (en) Methods comprising fixed intermittent dosing of cediranib
CN111295193A (zh) 组合疗法
WO2021180027A1 (zh) 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
CN115779095A (zh) 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合
JP2025159734A (ja) 抗線維化作用を有する低分子化合物と免疫チェックポイント制御剤との併用によるがん療法
CN118159538A (zh) 含met受体酪氨酸激酶抑制剂的药物组合及应用
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
TW202535407A (zh) 治療癌症的方法